Before You Invest, Make Sure You Check This 10x Genomics, Inc. (NASDAQ:TXG) Analysis

This article was originally published on this site

10x Genomics, Inc. (NASDAQ:TXG) concluded the trading at $190.41 on Friday, Jul 09 with a rise of 1.15% from its closing price on previous day.

>> 7 Top Picks for the Post-Pandemic Economy <<

Taking a look at stock we notice that its last check on previous day was $188.25 and 5Y monthly beta was reading 0 with its price kept floating in the range of $183.60 and $191.26 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that TXG hit a high price of $208.99 and saw its price falling to a low level of $85.74 during that period. Over a period of past 1-month, stock came adding 2.23% in its value.

With its current market valuation of $20.8 Billion, 10x Genomics, Inc. is set to declare its quarterly results on August 04, 2021. TXG Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.26 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.68 for 2021 with estimates of that growing to -$0.26 in next year. These estimates are suggesting current year growth of -0.87% for EPS and -0.62% growth next year.

In contrast, when we review TXG stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 50% Buy. Long term indicators are suggesting an average of 100% Buy for it.

According to ratings assigned by 10 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 1 of them are recommending 10x Genomics, Inc. (TXG) as a Hold, while 8 are in view that stock is a Buy. Recommendation by 1 analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the TXG stock which is currently positioned at 0. It further provides that stock’s current price level is -1.77% away from its 20-day simple moving average and is 7.05% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 51.65 while volatility remained at 4.38% over the past week which changes to 3.94% when measuring it over the past month. Beta is valued at 0, while measure of average true range or ATR is currently at 7.87. In predicting price targets of as low as $175 and as high as $240, analysts are in agreement on assigning the stock over the next 12 months average price target of $205. Stock’s current price level is -8.09% above from estimated low price target while it is 26.04% below the estimated high; and even if the TXG’s share succeeded to reach the median price of $202.5, then the outlook of +6.35% could come to the excitement of the investors.

In comparing 10x Genomics, Inc. (TXG)’s stock with other industry players reveals that stock’s current price change of +1.15% and that of +106.32% over the past 12 months is in better position with that of Cerner Corp (CERN) which saw its stock price fell by -0.21% in the last trading and went through an increase of 14.28% in past 12-month trading. Industry’s another major player Syneos Health Inc (SYNH) has fell -0.52% down in previous session, but over the past year has faced a rise of 61.88%, while Change Healthcare Inc (CHNG) was also up 1.15% however its price remained floating in the green at 106.32% over the same period. 10x Genomics, Inc. has a P/E ratio of 0 against that of Cerner Corp’s 30.45 while Syneos Health Inc is showing 48.5 for the same. On the other hand, the S&P 500 Index was up 1.13% in the last trading session while the Dow Jones Industrial closed the session higher at 1.3%.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!


Having a second look at 10x Genomics, Inc. (NASDAQ:TXG) provides that stock’s average daily trading volume for 3 months was 872.39 Million, while it dropped to 605.08 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 86.07 Million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 2.13% while it is 84.67% for the institutional holders. The figures also indicate that as of May 27, 2021, number of stock’s short shares was 2420000 which implies a short ratio of 2.3. This shows up a 2.2% of Short Interest in company’s outstanding shares on the day. In May the standing of shares short improved as it was 1.38 Million in the previous month. Addition of +34.47% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.